Daewoong Pharmaceutical Co. LTD.
Daewoong Pharmaceutical Co. LTD.
Explore linked clinical trials.38 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of DWP450 in Japanese Subjects With Glabellar Lines | Glabellar Lines | Not yet recruiting | Phase 3 | 2026-08-26 | NCT07783763 | |
| Efficacy and Safety of DWP14012 for Long-Term Maintenance Therapy in Patients With Healed Erosive Esophagitis | Healed Erosive Esophagitis | Not yet recruiting | Phase 3 | 2026-08-13 | NCT07746518 | |
| Phase 3 to Evaluate the Efficacy and Safety of DWP14012 in Patients With Gastric Ulcer | Digestive System Diseases, digestive system disorder, duodenal disorder, duodenal ulcer, gastric ulcer, intestinal disorder, peptic ulcer disease, stomach disorder | Not yet recruiting | Phase 3 | 2026-07-28 | NCT07730138 | |
| A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutrition, type 2 diabetes mellitus | Recruiting | Phase 1 | 2026-07-16 | NCT07539415 | |
| Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF | idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Active, not recruiting | Phase 2 | 2026-07-16 | NCT05389215 | |
| ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement | Ventricular Outflow Obstruction, aortic valve disorder, aortic valve stenosis, cardiovascular disorder, heart disorder, heart failure, heart valve disorder | Recruiting | Phase 4 | 2026-06-29 | NCT05672836 | |
| Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP212525 in Healthy Volunteers | autoimmune disease, immune system disorder | Recruiting | Phase 1 | 2026-06-08 | NCT06736587 | |
| To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes Mellitus | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Not yet recruiting | Phase 3 | 2026-06-02 | NCT07619833 | |
| Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, cancer, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 1 | 2026-05-08 | NCT07371104 | |
| Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Recruiting | Phase 4 | 2026-05-05 | NCT06399835 | |
| Fexuclue for Prevention of NSAIDs-Induced Peptic Ulcer in Real-World Practice | Digestive System Diseases, digestive system disorder, duodenal disorder, intestinal disorder, peptic ulcer disease, stomach disorder | Not yet recruiting | Not stated | 2026-04-30 | NCT07558707 | |
| CART BP Pro-Guided Blood Pressure Management for Uncontrolled Hypertension | cardiovascular disorder, hypertensive disorder, vascular disorder | Recruiting | Not applicable | 2026-04-30 | NCT07465549 | |
| Study to Evaluate the Efficacy and Safety of Fexuprazan in Prevention of NSAIDs Induced Peptic Ulcer | NSAID (Non-Steroidal Anti-Inflammatory Drug) | Not yet recruiting | Phase 4 | 2026-04-16 | NCT07533266 | |
| Noseguard for Prevention of Respiratory Infections in Real-World Use | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, influenza, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Not yet recruiting | Not applicable | 2026-04-08 | NCT07516977 | |
| Fexuprazan for Prevention of Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy | Arterial Occlusive Diseases, acute coronary syndrome, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Recruiting | Not applicable | 2026-04-08 | NCT07479056 | |
| Observational Study to Evaluate the Efficacy of OLMETEC Tab on Nocturnal Blood Pressure Control in Patients With Stage Ⅰ Hypertension | cardiovascular disorder, hypertensive disorder, vascular disorder | Recruiting | Not stated | 2026-04-07 | NCT07515599 | |
| Efficacy and Safety of Baroezet Tablet in Korean Patients With Dyslipidemia: A Prospective Observational Study | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, metabolic disease | Not yet recruiting | Not stated | 2026-04-07 | NCT07515560 | |
| Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION) | Arterial Occlusive Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Recruiting | Phase 4 | 2025-12-31 | NCT05845489 | |
| Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation | cardiovascular disorder, heart disorder, heart valve disorder, tricuspid valve insufficiency | Active, not recruiting | Phase 3 | 2025-12-29 | NCT06027307 | |
| Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1622, DWC202313, and DWC202314 in Healthy Volunteers Under Fasting Conditions | Healthy Volunteers | Recruiting | Phase 1 | 2025-12-17 | NCT07260851 | |
| Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition. | Healthy Volunteers | Recruiting | Phase 1 | 2025-12-05 | NCT07267221 | |
| Phase 4 Multicenter, Open-label Study on Efficacy and Safety of Apremilast in Moderate-to-severe Psoriasis | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, psoriasis, skin disorder | Not yet recruiting | Not stated | 2025-09-24 | NCT07190391 | |
| Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutrition, type 2 diabetes mellitus | Recruiting | Phase 4 | 2025-09-02 | NCT06782139 | |
| Registry Study to Determine the Effectiveness and Safety of Weight Loss With Enavogliflozin in Patients With Type 2 Diabetes Mellitus | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Active, not recruiting | Not stated | 2025-09-02 | NCT06427083 | |
| Effect of Linking Data Using Smartphone Application, 'Well Check', on Clinical Outcomes in Patients With Type 2 Diabetes Mellitus | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Active, not recruiting | Not stated | 2025-09-02 | NCT06419816 |